| Literature DB >> 29309998 |
Przemysław Paweł Taciak1, Natalia Lysenko2, Aleksander Paweł Mazurek3.
Abstract
Depression is nowadays a major contributor to global burden of disease. The most commonly prescribed drugs influence monoaminergic pathways, mainly concentrating on serotonin. Unfortunately, there are several drawbacks associated with these drugs, namely late onset of action, risk of suicide and adverse effects: mainly nausea, vomiting and sexual dysfunction. Therefore there is still need for new drugs with possibly high efficacy and fewer side effects. In this paper selected compounds which inhibit serotonin reuptake by acting on the serotonin transporter (SERT) and various serotoninergic receptors are presented. We also discuss the ways in which their mechanism of action can be modified to improve pharmacological profile. Here, we focus on describing drugs' potency, efficacy and adverse effects. Additional applications, apart from depression, are also discussed.Entities:
Keywords: Antidepressants; Major depressive disorder; Monoamine reuptake inhibitors; Serotonergic receptors; Serotonin transporter
Mesh:
Substances:
Year: 2017 PMID: 29309998 DOI: 10.1016/j.pharep.2017.07.011
Source DB: PubMed Journal: Pharmacol Rep ISSN: 1734-1140 Impact factor: 3.024